Posted by: В.В. Kaminskyi, V.V. Konoplianko, M.N. Shalko, N.Ya. Ratushniak.
Department of Obstetrics, Gynecology and Reproductology of the NMAPE named after P.L. Shupyk
Kyiv City Center for Reproductive and Perinatal Medicine.
Publication Place: Reproductive Health. Eastern Europe. 2018, Volume 8, №1.
The article presents the results of the study of the effectiveness of the drug Proginorm OVO and Proginorm GESTA in the schemes of complex therapy of the threat of termination of pregnancy and the threat of premature birth. 290 pregnancies with the risk of interruption or the risk of preterm birth were analyzed at different times. Women groups were representative of age, parity, place of residence, social status, and somatic health status. the efficacy in the treatment regimen of the oral form of natural micronized progesterone Proginorm OVO 100 mg, 200mg and vaginal form Progestin GESTA 100 mg, 200mg with individual selection of therapeutic dose from 200mg to 400mg per day were compared. The method of administration is selected taking into account the presence or absence of changes in the microcenosis of the vagina, the intestinal function of the intestine and as an individual choice of pregnant without pathologies of these systems of the body. During treatment, faster regression of clinical symptoms in the study groups was observed.
Complex therapy of the threat of pregnancy termination and the threat of premature birth with the use of oral and vaginal forms of micronized progesterone has a high therapeutic effect, is well tolerated, contributes to a shorter period of stay in hospital and stay of a pregnant woman in intense psycho-emotional connection pregnancy.
The presence of oral and vaginal form in the drug allows to individually approach to each case the threat of abortion or premature birth, taking into account concomitant pathologies and convenience for the patient, if necessary, to switch from one form to another, for rapid saturation of the body of pregnant progestogen by elimination of gestational in conditions of the risk of termination of pregnancy or prolongation of pregnancy in the threat of premature birth, may be recommended for use in a wide obstetric practice.
Keywords: micronized progesterone, threat of preterm birth, Proginorm GESTA, vaginal dosage form, Proginorm OVO, oral dosage form.